These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12788194)

  • 1. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.
    Gupta AK; Cerniglia GJ; Mick R; Ahmed MS; Bakanauskas VJ; Muschel RJ; McKenna WG
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):846-53. PubMed ID: 12788194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
    Liu Y; Cui B; Qiao Y; Zhang Y; Tian Y; Jiang J; Ma D; Kong B
    Int J Gynecol Cancer; 2011 Jan; 21(1):100-5. PubMed ID: 21330835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.
    Fujiwara M; Izuishi K; Sano T; Hossain MA; Kimura S; Masaki T; Suzuki Y
    J Exp Clin Cancer Res; 2008 Nov; 27(1):76. PubMed ID: 19032736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells.
    Semba S; Itoh N; Ito M; Harada M; Yamakawa M
    Clin Cancer Res; 2002 Jun; 8(6):1957-63. PubMed ID: 12060641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.
    Gupta AK; McKenna WG; Weber CN; Feldman MD; Goldsmith JD; Mick R; Machtay M; Rosenthal DI; Bakanauskas VJ; Cerniglia GJ; Bernhard EJ; Weber RS; Muschel RJ
    Clin Cancer Res; 2002 Mar; 8(3):885-92. PubMed ID: 11895923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
    Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
    Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer.
    Li P; Zhang Q; Torossian A; Li ZB; Xu WC; Lu B; Fu S
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e391-7. PubMed ID: 22414288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
    Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
    Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
    Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
    Urol Int; 2011; 87(1):105-13. PubMed ID: 21597260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
    Xie X; Tang B; Zhou J; Gao Q; Zhang P
    Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas.
    Van Meter TE; Broaddus WC; Cash D; Fillmore H
    Cancer; 2006 Nov; 107(10):2446-54. PubMed ID: 17041888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells.
    Xia S; Zhao Y; Yu S; Zhang M
    Cancer Biother Radiopharm; 2010 Jun; 25(3):317-23. PubMed ID: 20578837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
    Nakamura JL; Karlsson A; Arvold ND; Gottschalk AR; Pieper RO; Stokoe D; Haas-Kogan DA
    J Neurooncol; 2005 Feb; 71(3):215-22. PubMed ID: 15735908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
    Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation.
    Edwards E; Geng L; Tan J; Onishko H; Donnelly E; Hallahan DE
    Cancer Res; 2002 Aug; 62(16):4671-7. PubMed ID: 12183424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway.
    Poh TW; Pervaiz S
    Cancer Res; 2005 Jul; 65(14):6264-74. PubMed ID: 16024628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.
    Tenzer A; Zingg D; Rocha S; Hemmings B; Fabbro D; Glanzmann C; Schubiger PA; Bodis S; Pruschy M
    Cancer Res; 2001 Nov; 61(22):8203-10. PubMed ID: 11719451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.